Martek Biosciences (MATK) Tops Q2 EPS by 4c; Guides
More News related to MATK
- Canaccord Adams Reiterates a 'Buy' Rating on NBTY (NTY), Adds to Best Ideas List
- Martek's life'sDHA(TM) Featured in New Nutrioli DHA Cooking Oil from Ragasa
- Martek Announces Addition to Its Board of Directors
- Martek to Present at Two Upcoming Investor Conferences
- Martek (MTK) Announces Settlement of Patent Dispute with Capsugel France
More News related to Earnings
- After-Hours Movers 11/09: SGK, PCLN, SQNM Higher; MBI, SDTH, UTK, TOPS, CPST, BTN, FLR Lower
- Trading Radar for 11/10: Tyco Int. (TYC), ArvinMeritor (ARM), Clearwire (CLWR), American Apparel (APP) Report
- Unusual 11 Mid-Day Movers 11/09: EONC, EWBC, REV, PRST Higher; GTN, CHNG, SRZ, CHDX Lower
- Notable Analyst Rating Changes: RSH, ANF, NOC, ADBE, HERO Upgraded; RIMM, RHT, GPS, AZN, SGY Downgraded
- Morning Movers 11/09: EWBC, CVM, REV, CGEN, RSH Higher; CHDX, SRZ, GTN, RPRX, VSR Lower
Martek Biosciences Corporation (Nasdaq: MATK) reports Q2 EPS of $0.33, 4 cents better than the analyst estimate of $0.. Revenue for the quarter was $92.4 million, versus the consensus of $89.4 million.
Martek Biosciences sees FY EPS of $1.20-$1.25, versus the consensus of $1.23. Sees FY revenues of $350-$355 million, versus the consensus of $365.1 million.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
